Adam covers proteomics and life science mass spectrometry for GenomeWeb.
The assay could be useful for identifying patients who are HER2-negative by conventional IHC but who are likely to benefit from newer anti-HER2 therapies.
The single-cell omics company recently awarded $100,000 in grants funding research on its platform and published on its use for characterizing CAR-T cells.
The study identified multiple clusters of engineered natural killer T cells based on RNA-seq and found that they could be effective against the disease.
The work suggests mass spec can more accurately assess levels of immunotherapy targets like PD-L1 than conventional clinical approaches.
The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.
The DoD and VA-led initiative is moving beyond its initial focus on lung cancer to add analyses of multiple cancer types and a prospective, multisite study.
The Singapore-based firm plans to use its single-cell RNA and protein assay to help optimize the production of CAR T cells and guide their use in patients.
The companies are developing PET tracers based on Indi's affinity agent technology that will allow for imaging-based detection of cytotoxic T lymphocyctes.
In work presented at the recent American Association for Cancer Research annual meeting, they found that T-cell cytokine production predicted patient response.